TILT Biotherapeutics has raised $25.6 million in Series B funding to advance TILT-123, an oncolytic adenovirus engineered to enhance immune response against tumors, into Phase 2 trials for platinum-resistant ovarian cancer.
Shionogi & Co. plans to acquire Japan Tobacco's pharmaceutical subsidiaries Torii Pharmaceutical and Akros Pharma for ¥160 billion ($1.1 billion) to strengthen its global R&D capabilities.
DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.
The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.